Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A targeted IL-15 fusion protein with potent anti-tumor activity.

Literature DB >> 26176990

A targeted IL-15 fusion protein with potent anti-tumor activity.

Siqi Chen^1,2, Qiang Huang^1,2, Jiayu Liu^1,2, Jieyu Xing^1,2, Ning Zhang³, Yawei Liu⁴, Zhong Wang^1,2, Qing Li^1,2.

Abstract

IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, the novel PFC-1 construct was designed, which comprises the following 3 parts: (1) IL-15Rα fused with IL-15 to enhance IL-15 activity, (2) an Fc fragment to increase protein half-life, and (3) an integrin-targeting RGD peptide to enhance tumor targeting. PFC-1 showed tumor cell targeting without compromising IL-15 activity. PFC-1 also had potent anti-tumor activities in xenograft models, suggesting the potential application of this multi-functional fusion protein in tumor therapy.

Entities: Disease Gene

Keywords: IL-15; IL-15Rα; RGD; fusion protein; tumor immunotherapy

Mesh：

Substances：

Year: 2015 PMID： 26176990 PMCID： PMC4622986 DOI： 10.1080/15384047.2015.1071739

Source DB: PubMed Journal: Cancer Biol Ther ISSN： 1538-4047 Impact factor: 4.742

28 in total

1. Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15.

Authors: Toshimasa Kukita; Naomichi Arima; Kakushi Matsushita; Kosei Arimura; Hideo Ohtsubo; Yoshimune Sakaki; Hiroshi Fujiwara; Atsuo Ozaki; Tadashi Matsumoto; Chuwa Tei
Journal: Br J Haematol Date: 2002-11 Impact factor: 6.998

2. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.

Authors: Huile Gao; Yang Xiong; Shuang Zhang; Zhi Yang; Shijie Cao; Xinguo Jiang
Journal: Mol Pharm Date: 2014-02-19 Impact factor: 4.939

3. Intracellular targets of RGDS peptide in melanoma cells.

Authors: Maria Simona Aguzzi; Paola Fortugno; Claudia Giampietri; Gianluca Ragone; Maurizio C Capogrossi; Antonio Facchiano
Journal: Mol Cancer Date: 2010-04-22 Impact factor: 27.401

4. Novel human interleukin-15 agonists.

Authors: Xiaoyun Zhu; Warren D Marcus; Wenxin Xu; Hyung-il Lee; Kaiping Han; Jack O Egan; Jason L Yovandich; Peter R Rhode; Hing C Wong
Journal: J Immunol Date: 2009-08-26 Impact factor: 5.422

Review 5. Twelve immunotherapy drugs that could cure cancers.

Authors: Martin A Cheever
Journal: Immunol Rev Date: 2008-04 Impact factor: 12.988

6. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression.

Authors: Yung-Luen Yu; Chyou-Wei Wei; Yi-Lin Chen; Mark Hung-Chih Chen; Giou-Teng Yiang
Journal: Int J Oncol Date: 2010-02 Impact factor: 5.650

7. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha.

Authors: Grégory Bouchaud; Laure Garrigue-Antar; Véronique Solé; Agnès Quéméner; Yvan Boublik; Erwan Mortier; Harmonie Perdreau; Yannick Jacques; Ariane Plet
Journal: J Mol Biol Date: 2008-07-16 Impact factor: 5.469

8. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.

Authors: Sigrid Dubois; Hiral J Patel; Meili Zhang; Thomas A Waldmann; Jürgen R Müller
Journal: J Immunol Date: 2008-02-15 Impact factor: 5.422

9. Integrin targeted delivery of chemotherapeutics.

Authors: Kai Chen; Xiaoyuan Chen
Journal: Theranostics Date: 2011-02-17 Impact factor: 11.556

10. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation.

Authors: Erwan Mortier; Tammy Woo; Rommel Advincula; Sara Gozalo; Averil Ma
Journal: J Exp Med Date: 2008-05-05 Impact factor: 14.307

9 in total

Review 1. Bispecific antibodies in cancer immunotherapy.

Authors: Siqi Chen; Jing Li; Qing Li; Zhong Wang
Journal: Hum Vaccin Immunother Date: 2016-06-01 Impact factor: 3.452

Review 2. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors: Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2018-02-15 Impact factor: 8.110

Review 3. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Authors: Xiaohu Zheng; Yaqi Wu; Jiacheng Bi; Yingying Huang; Ying Cheng; Yangyang Li; Yuwei Wu; Guoshuai Cao; Zhigang Tian
Journal: Cell Mol Immunol Date: 2022-01-04 Impact factor: 11.530

4. BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.

Authors: Jieyu Xing; Limin Lin; Jing Li; Jiayu Liu; Changhua Zhou; Haitao Pan; Rui Shu; Bin Dong; Donglin Cao; Qing Li; Zhong Wang
Journal: Transl Oncol Date: 2017-08-07 Impact factor: 4.243

5. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.

Authors: Renee N Donahue; Lauren M Lepone; James L Gulley; Jeffrey Schlom; Italia Grenga; Caroline Jochems; Massimo Fantini; Ravi A Madan; Christopher R Heery
Journal: J Immunother Cancer Date: 2017-02-21 Impact factor: 13.751